206 results
8-K
EX-10.1
NBSE
NeuBase Therapeutics Inc
26 Jan 24
Entry into a Material Definitive Agreement
8:00am
and is in good standing (if a good standing concept exists in such jurisdiction) as a foreign corporation or other entity in each jurisdiction in which the nature
8-K
EX-10.1
NBSE
NeuBase Therapeutics Inc
28 Dec 23
Termination of a Material Definitive Agreement
7:00am
and expenses (including, without limitation, all legal fees, interest, or penalties) of every kind, name, nature, and description whether arising out … of contract, tort, or otherwise, in law or equity, of whatsoever kind or nature, whether liquidated or unliquidated, matured or unmatured, known or unknown
8-K
EX-10.1
3ktrmbxvghvsi3z
18 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
y36 cjlcl
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-10.3
wk4y6or
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-10.2
w582rlrlv paa
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
424B5
zqc9c4k
30 Jun 23
Prospectus supplement for primary offering
8:42am
10-QT
2q62yrwtxrf
5 Jun 23
Quarterly report for transitional period
4:05pm
8-K
EX-99.2
fkdycnef1pm zfb
22 May 23
Regulation FD Disclosure
7:00am
424B5
5c59qh980g33rwy
29 Dec 22
Prospectus supplement for primary offering
5:03pm
8-K
EX-10.1
4pqlbrwpmqwii1y2mag
29 Dec 22
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
qs3eq74wys09k 3vfh1
21 Dec 22
NeuBase Therapeutics Reports Business Update and Financial Results
8:10am